Den 7. december 2006 underrettede Fournier Laboratories Ireland Ltd. officielt Udvalget for Human - medicinske Lægemidler (CHMP) om, at firmaet ønskede at trække sin ansøgning om markedsførings - tilladelse tilbage for lægemidlet Synordia, indiceret til forbedring af glykæmisk kontrol og dyslipidæ - mi hos patienter med type 2- sukkersyge.
On 7 December 2006, Fournier Laboratories Ireland Ltd officially notified the Committee for Medicinal Products for Human Use (CHMP) that they wish to withdraw their application for a marketing authorisation for Synordia, for the improvement of glycaemic control and dyslipidaemia in patients with type 2 diabetes.